Expect to See Crizanlizumab or Voxelotor for Some Sickle Cell Patients
Crizanlizumab (Adakveo, ah-DAK-vee-oh) and voxelotor (Oxbryta, oks-BRYE-tuh) will be new meds for sickle cell disease.
They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.
And they’ll compete with oral L-glutamine (Endari)...which seems to reduce pain crises and possibly hospitalizations.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote